US equities
|
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MU
$934.27
▼-4.98%
MSFT
$530.14
▼-0.16%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MU
$934.27
▼-4.98%
MSFT
$530.14
▼-0.16%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Tango Therapeutics, Inc.
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
October 23, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
October 16, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 01, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Executive Chair Transition
August 06, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Appoints Robert Azelby to Board of Directors
June 22, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 09, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Proposed $500 Million Public Offering
June 08, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 08, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
November 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 07, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 08, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 18, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
September 30, 2021
From
Tango Therapeutics, Inc.
Via
Business Wire
Tickers
TNGX
